ReviewAntibodies (Basel, Switzerland)2024
Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic Management.
Review in Antibodies (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- The Patient Experience of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Post-Diagnosis: Results from an International Survey.Neurology and therapy · 2026Article
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Cerebral Cortical Encephalitis: A Comparative Study With Antibody-Negative and Non-MOG Antibody-Positive Cortical Encephalitis in Chinese Adults.CNS neuroscience & therapeutics · 2026Article
- Clinical and laboratory findings in patients with anti-myelin oligodendrocyte glycoprotein antibodies: experience from two tertiary hospitals in Madrid.Frontiers in immunology · 2026Article
- Neurological graft-versus-host disease with MOG antibody positivity after allogeneic stem cell transplantation: a case report.Frontiers in immunology · 2026Article
- A Case Report of Rare MOG Antibody-Associated Optic Neuritis Related to Hepatitis E Virus Infection.Infection and drug resistance · 2026Article
- The relationship between serum MOG-IgG titer status and titers and the prognosis of pediatric MOGAD: a retrospective cohort study.Frontiers in pediatrics · 2026Article
- Epidural labor analgesia in a pregnant woman with symptomatic recurrence of myelin oligodendrocyte glycoprotein antibody-associated disease: a case report.JA clinical reports · 2025Article
- Predictors of relapse and disability in NMOSD, MOGAD, and double-seronegative demyelinating syndromes: an international multicenter retrospective cohort study.Journal of neurology · 2025Article
- MOGAD: A Shifting Landscape-From Pathogenesis to Personalised Management, Global Perspectives and Latin American Insights.Biomedicines · 2025Review
- Diversity, Functional Complexity, and Translational Potential of Glial Cells in the Central Nervous System.International journal of molecular sciences · 2025Review
- Translational insights from EAE models : decoding MOGAD pathogenesis and therapeutic innovation.Frontiers in immunology · 2025Review
- Myelin oligodendrocyte glycoprotein antibody-associated cerebral cortical encephalitis: a case report highlighting diagnostic challenges and therapeutic implications.Frontiers in immunology · 2025Article
- A Challenging Case of MOG-Associated Optic Neuritis: The Role of IL-6 Inhibition in Refractory Disease.International medical case reports journal · 2025Article
- Myelin Oligodendrocyte Glycoprotein Antibody Disease - MOGAD.Indian journal of pediatrics · 2025Article
- Cerebellar tumefactive demyelination in MOGAD: a case report on diagnostic challenges and immunotherapeutic strategy.Frontiers in immunology · 2025Article
- Unveiling GFAP Astrocytopathy: Insights from Case Studies and a Comprehensive Review of the Literature.Antibodies (Basel, Switzerland) · 2024Review
- Case report: Overlapping syndrome of MOG-IgG associated optic neuritis and autoimmune encephalitis with co-existence of anti-NMDAR and anti-GABAFrontiers in immunology · 2024Article
- Pediatric Meningitis-Retention Syndrome With Anti-MOG Antibodies: A Report of Two Cases.Pediatrics international : official journal of the Japan Pediatric SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical syndromes associated with antibodies against myelin oligodendrocyte glycoprotein (MOG) are now recognized as a distinct neurological disease entity, and are gaining increasing attention. The pathogenic mechanisms underlying MOG-antibody disease (MOGAD) remain incompletely understood. Case series, facilitated by registries, and observational studies over the past few years have shed increasing light on the clinical aspects and therapeutic approaches of MOGAD. MOGAD may manifest with a variety of clinical syndromes, including acute disseminated encephalomyelitis (ADEM), autoimmune encephalitis, optic neuritis (ON) and transverse myelitis (TM). MOGAD can be either monophasic or relapsing. This review aims to provide a comprehensive updated description of the clinical spectrum, paraclinical features, and prognosis of MOG-antibody disease, as well as summarize its therapeutic considerations. Randomized clinical trials, standardized diagnostic criteria and treatment guidelines are the steps forward.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.